Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300736 | 0.82 | ADORA2A (0.57) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL5689599 | 0.75 | ADORA2A (0.37) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL724838 | 0.73 | ADORA2A (0.47) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL1081739 | 0.70 | ADORA2A (0.57) | ADORA2AADORA2BADORA3ADORA1 | |
| Hydrochloric Acid SCHEMBL6754870 | 0.70 | ADORA2A (0.56) | ADORA2AADORA2BADORA3ADORA1 | |
| Hydrochloric Acid SCHEMBL2031973 | 0.69 | ADORA2A (0.55) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL940191 | 0.68 | ADORA2A (0.46) | ADORA2AADORA2BADORA3 | |
| SCHEMBL2295173 | 0.68 | ADORA2A (0.48) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL846742 | 0.66 | HSPA8 (0.46) | ADORA2AADORA2BADORA3ADORA1 | |
| SCHEMBL29384918 | 0.64 | ADORA2A (0.67) | ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20190307678-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2019-10-10 | — | — | US | disclosed |
| US-10272034-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2016-08-25 | — | — | US | disclosed |
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9132087-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20120277199-A1 | Modulation of Gel Temperature of Poloxamer-Containing Formulations | OTONOMY, INC. (US) | 2012-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243028-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | ADORA2A 24/4885ADORA2B 35/4885ADORA3 84/4885 |
| US-20190307678-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | ADORA2A 24/4885ADORA2B 35/4885ADORA3 84/4885 |
| US-10751281-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | ADORA2A 24/4885ADORA2B 35/4885ADORA3 84/4885 |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | ADORA2A 24/4885ADORA2B 35/4885ADORA3 84/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | ADORA2A 24/4885ADORA2B 35/4885ADORA3 84/4885 |
| US-10272034-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | ADORA2A 24/4885ADORA2B 35/4885ADORA3 84/4885 |
| US-20160228357-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | ADORA2A 24/4885ADORA2B 35/4885ADORA3 84/4885 |
| US-20120277199-A1 | Modulation of Gel Temperature of Poloxamer-Containing Formulations | PTGIR, HSPH1, HSP90AA1 | ADORA2A 1279/4885ADORA2B 2150/4885ADORA3 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.